GlobeNewswire by notified

U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)

Share
  • FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be appropriate
  • This approval marks the first and only companion diagnostic indication for Rozlytrek, and another important milestone in tumour-agnostic approaches for people living with rare cancers
  • Roche is a leader in driving personalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug development

Basel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (U.S. FDA) has approved Foundation Medicine’s FoundationOne®CDx as a companion diagnostic (CDx) for Roche’s Rozlytrek® (entrectinib). FoundationOne CDx is a comprehensive genomic profiling (CGP) pan-tumour tissue biopsy test that assesses an individual’s cancer to identify the unique molecular ‘fingerprint’ of the tumour. It is the first and only U.S. FDA-approved CDx to identify patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC), or patients with NTRK fusion-positive cancers, for whom treatment with Rozlytrek may be appropriate.

“The ability to tailor cancer therapies based on specific genomic alterations using validated comprehensive genomic profiling (CGP) has transformed the traditional ‘one-size fits-all’ approach to cancer,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval marks a significant step forward in expanding treatment options and improving outcomes for patients, particularly those with rare tumours.”

Using CGP to identify the genomic alterations that are associated with driving an individual’s cancer can support physicians in making an informed treatment decision for the individual patient, potentially achieving better clinical outcomes.1

Rozlytrek is a targeted therapy approved to treat ROS1 fusion-positive metastatic NSCLC and a tumour-agnostic medicine for locally advanced or solid tumours that harbour NTRK fusions. ROS1 gene fusions account for 1-2% of NSCLC, the most common type of lung cancer that accounts for up to 85% of all diagnoses.2,3 NTRK gene fusions have been identified in a range of solid tumour types, and are present in up to 90% of some rare cancer types and less than 1% of other more common cancers, including lung and colorectal.4

The approval is based on data from the phase I ALKA-372-001 (EudraCT 2012-000148-88), phase I STARTRK-1 (NCT02097810) and phase II STARKTRK-2 (NCT02568267) trials. As a condition of this approval, Foundation Medicine will conduct a post-approval study powered by the Flatiron Health-Foundation Medicine’s Clinico-Genomic Database (CGDB) to further demonstrate FoundationOne CDx’s ability to identify patients with ROS1 fusion-mutated NSCLC for whom treatment with Rozlytrek may be appropriate. The CGDB is a de-identified, HIPAA-compliant database that links outcomes data from Flatiron’s network of oncology clinics and genomic data from Foundation Medicine’s CGP assays. The database currently contains more than 100,000 linked genomic profiles , and is continually growing.

By combining tumour-agnostic drug development with data collection, high-quality diagnostics and the implementation of CGP, Roche is leading the realisation of personalised healthcare around the world, enabling physicians to develop tailored treatment strategies for each individual, and enable smarter, more efficient research and development to ensure no person is left behind.

About FoundationOne®CDx
FoundationOne CDx is a next-generation sequencing-based in vitro diagnostic assay for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures, including microsatellite instability and tumour mutational burden, using DNA isolated from formalin-fixed paraffin embedded tumour tissue specimens. FoundationOne CDx is for prescription-use only and is intended as a companion diagnostic (CDx) to identify people who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumour mutation profiling to be used by qualified healthcare professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy.

FoundationOne CDx was approved by the United States Food and Drug Administration in November 2017 and is currently approved as a CDx for 25 CDx indications, and three group claims across 30 targeted therapies. For a full list of targeted therapies for which FoundationOne CDx is indicated as a CDx, please visit http://www.foundationmedicine.com/genomic-testing/foundation-one-cdx

About Rozlytrek® (entrectinib)
Rozlytrek is a tumour-agnostic once-daily oral medicine for the treatment of locally advanced or metastatic solid tumours that harbour NTRK1/2/3 or ROS1 gene fusions. It is a selective tyrosine kinase inhibitor designed to inhibit the kinase activity of the TRKA/B/C and ROS1 proteins, whose activating fusions drive proliferation in certain types of cancer. Rozlytrek can block NTRK and ROS1 kinase activity and may result in the death of cancer cells with NTRK or ROS1 gene fusions.

Rozlytrek is approved for the treatment of NTRK fusion-positive solid tumours and ROS1 fusion-positive non-small cell lung cancer by health authorities in more than 60 countries, including by the United States Food and Drug Administration (U.S. FDA), Japan’s Ministry of Health, Labour and Welfare (MHLW) and the European Medicines Agency (EMA). Prior to approval, Rozlytrek was granted Breakthrough Therapy Designation by the U.S. FDA, Sakigake designation for accelerated review by Japan’s MHLW, and Priority Medicines designation by the EMA.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Singal G, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database. JAMA. 2019;321(14):1391–1399.
[2] Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013; 18(7):865–75.
[3] The American Cancer Society. What is lung cancer? [Internet; cited Apr 2022]. Available from: https://www.cancer.org/cancer/lung-cancer/about/what-is.html
[4] Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 61 687 41 47
SileiaUrech
Phone: +41 79 935 81 48

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
KarstenKleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc’s share buybacks 28/06/202229.6.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 29/06/2022 at 08:30 am Sampo plc’s share buybacks 28/06/2022 On 28/06/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,24842.24AQEU24,42242.25CEUX8,67542.27TQEX85,16742.21XHELTOTAL132,51242.22 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 1,841,919 Sampo A shares representing 0.35 per cent of the total number of shares in Sampo plc. Details of ea

IMCD recognised by Sustainalytics as 2022 ESG Industry Top Performer, ranking first among traders and distributors29.6.2022 07:00:00 CEST | Press release

ROTTERDAM, The Netherlands (29 June 2022) – IMCD N.V., (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, was recognised by Sustainalytics as an ESG Industry Top Rated Company. With a score of 13.8 (low risk) IMCD ranks first (lowest risk) among over 180 international peers in trading and distribution. It places the company in the top seven percent of almost 15,000 companies assessed worldwide. Sustainalytics, a Morningstar company, is a globally recognised provider of ESG research, ratings and data that supports investors around the world with the development and implementation of responsible investment strategies. Its ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks. In March 2022, IMCD was also included in the newly launched Dutch ESG AEX index, as one of 25 companies demonstrating best Environmental, Social and Governance (ESG) practices. “We are excited and proud

Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care29.6.2022 07:00:00 CEST | Press release

The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients.With laboratory diagnostics involved in more than two-thirds of healthcare decision making, innovative laboratory solutions that enable an accurate and timely diagnosis are crucial to successful treatment.About 17 million new cases of cancer are diagnosed worldwide each year, and nearly 10 million people die from the disease.1 Basel, 29 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey. “With the BenchMark ULTRA PLUS, we are pleased to offer an advanced tissue staining platform, co-developed with lab professionals,” said Thomas Schinec

SIKA EXPANDS PRODUCTION OF CONCRETE ADMIXTURES IN THE USA29.6.2022 07:00:00 CEST | Press release

SIKA EXPANDS PRODUCTION OF CONCRETE ADMIXTURES IN THE USA Sika is bringing a new manufacturing plant for concrete admixtures on stream in Stafford, Virginia. With the opening of the plant near Washington D.C., Sika is increasing its production capacity in the important American construction market so that it can readily satisfy the strong demand in the Northeast and Mid-Atlantic regions. With over 75 million inhabitants, the urban centers in the Northeast, like New York, Philadelphia, or Boston, are very densely populated and account for more than 25% of US economic output. The new plant is well positioned to support the additional needs of the announced infrastructure program of CHF 200-250 billion in the aforementioned two regions. Sika has been benefiting from the strong demand in the construction sector over recent years. The new facility in Stafford is the second-biggest manufacturing plant for Sika concrete admixtures in the USA. Together with the existing plant in Fairless Hills

TGS ASA and Magseis Fairfield ASA Announce a Recommended Voluntary Exchange Offer by TGS to Acquire All Shares of Magseis29.6.2022 07:00:00 CEST | Press release

OSLO, Norway (29 June 2022) - TGS ASA (“TGS”, OSE: TGS) and Magseis Fairfield ASA (“Magseis”, OSE: MSEIS) announce today that they have entered into a transaction agreement (the "Transaction Agreement") whereby TGS on and subject to certain terms and conditions will put forward a voluntary exchange offer (the “Offer”) to acquire all shares of Magseis for a consideration to the Magseis shareholders in the form of 0.0426 ordinary shares of TGS and NOK 2.30 in cash per Magseis share (the “OfferConsideration”). Based on the closing price of TGS on 28 June 2022, the value of the Offer Consideration is equal to NOK 8.6048 per Magseis share, and the Offer values the total issued share capital of Magseis at approximately NOK 2,333 million. The board of directors of Magseis (the "Board") has unanimously resolved to recommend the Offer. Magseis shareholders, including the largest shareholder, Fairfield MS, LLC, and members of the Magseis Board and management, who collectively own 33.4% of the ou